Notch

RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.

Valproic acid-d6 (VPA-d6) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins.

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC).

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that can inhibit the Notch1 signal. Brontictuzumab selectively binds to the negative regulatory region of Notch1. Brontictuzumab can inhibit tumor cell proliferation and is used in research for leukemia and lymphoma.

Tarlatamab is a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3).

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4.

JI130 (JI051 derivative ) is a stabilizer for the Hes1-PHB2 interaction.

Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody.

Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody.

Zocilurtatug pelitecan (ZL-1310) is a blood-brain barrier-penetrating antibody-drug conjugate targeting DLL3.

Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G.

TAS1440 is an orally active LSD1/KDM1A inhibitor with a human IC 50 of 4.8 nM.

CAD204520 dihydrochloride, a SERCA inhibitor ( IC 50 = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL).

PAI-1-IN-1 is an orally active and specific PAI-1 inhibitor with an IC 50 of <6.95 μM.

Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3.

Tangeretin is a naturally polymethoxylated flavone compound extracted from the citrus peel and acts as a Notch-1 inhibitor.